Combating the epigenome: epigenetic drugs against non-Hodgkin's lymphoma.

  title={Combating the epigenome: epigenetic drugs against non-Hodgkin's lymphoma.},
  author={Melanie R. Hassler and A Reagan Schiefer and Gerda Egger},
  volume={5 4},
Non-Hodgkin's lymphomas (NHLs) comprise a large and diverse group of neoplasms of lymphocyte origin with heterogeneous molecular features and clinical manifestations. Current therapies are based on standard chemotherapy, immunotherapy, radiation or stem cell transplantation. The discovery of recurrent mutations in epigenetic enzymes, such as chromatin modifiers and DNA methyltransferases, has provided researchers with a rationale to develop novel inhibitors targeting these enzymes. Several… CONTINUE READING
5 Citations
169 References
Similar Papers


Publications referenced by this paper.
Showing 1-10 of 169 references

Histone deacetylase inhibitor potentiates chemotherapy - induced apoptosis through Bim upregulation in Burkitt ’ s lymphoma cells

  • AC DosSantosFerreira, RA Fernandes, JK Kwee, CE Klumb
  • Am . J . Transl . Res .
  • 2013

Similar Papers

Loading similar papers…